Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Rashin MohseniPouya Mahdavi SharifMaryam BehfarMohammad Reza ModaresiRohola ShirzadiMahta MardaniLeila JafariFahimeh JafariZeynab NikfetratAmir Ali HamidiehPublished in: Stem cell research & therapy (2023)
AT-MSCs could be safely administered to our pediatric cases with BoS post-allo-HSCT. Considering their advanced stage of disease, their sub-optimal functional capacity due to steroid-induced complications, and COVID-19 infection post-treatment, we believe that AT-MSC therapy can have possible efficacy in the management of pediatric BoS. The conduction of further studies with larger sample sizes and more frequent injections is prudent for further optimization of AT-MSC therapy against BoS. Trial registration Iranian Registry of Clinical Trials (IRCT), IRCT20201202049568N2. Registered 22 February 2021, https://en.irct.ir/trial/53143 .
Keyphrases
- clinical trial
- allogeneic hematopoietic stem cell transplantation
- adipose tissue
- phase ii
- phase iii
- study protocol
- hematopoietic stem cell
- acute myeloid leukemia
- acute lymphoblastic leukemia
- stem cell transplantation
- mesenchymal stem cells
- type diabetes
- insulin resistance
- high glucose
- high fat diet
- case report
- risk factors
- low dose
- young adults
- high dose